Non-Hodgkin lymphoma comprises a heterogeneous group of haematological malignancies, classified according to their clinic, anatomic-pathological features and, lately, to their molecular biomarkers. Despite the therapeutic advances, nearly half of the patients will die because of this disease. The new diagnostic tools have been the cornerstone to design recent therapy targets, which must be included in the current treatment guidelines of this sort of neoplasms by means of clinical trials and evidence-based medicine.
View Article and Find Full Text PDFObjective: The aim of this study was to determine the reproducibility of the HERCEP-test (Dako Co. Carpintería Ca) for the assessment of HER-2/neu protein overexpression in archival tissues samples of women with ductal invasive breast carcinoma.
Materials And Methods: The study population was 40 retrospective and consecutive cases of women with ductal invasive breast carcinoma.